The FDA announced six additional medicines will receive Commissioner’s National Priority Vouchers (CNPVs), expanding a pilot intended to shorten review timelines for therapies aligned with U.S. national priorities. Winners include oral formulations tied to the administration’s obesity‑drug access initiatives, creating paths to decisions within months rather than standard 10–12 month reviews. The voucher program is closely linked to recent White House deals with major manufacturers; recipients reported faster regulatory windows in exchange for pricing concessions. The program has drawn praise for speeding access and criticism over potential market distortions and commercial incentives that could favor large incumbents. Industry stakeholders are assessing program mechanics, selection criteria and the impact on FDA workload and precedent. Developers may adjust filing strategies depending on whether CNPVs become a recurring avenue to accelerate approvals for high‑profile therapeutics.